A 32-year-old man presents with a 4-month history of pain and swelling in the proximal tibia. Clinical examination reveals mild warmth and tenderness over the proximal tibia. X-ray shows a lytic lesion in the proximal tibial metaphysis extending into the epiphysis, with a thin sclerotic rim. The lesion measures 4 cm and is well-demarcated. On MRI, there are areas of low signal intensity on T2-weighted images consistent with hemosiderin. The patient is counseled about the risk of recurrence. Which of the following is the most appropriate next step in management?

Explanation

## Giant Cell Tumor Management: Treatment Algorithm ### Clinical Context **Key Point:** This patient has a classic giant cell tumor (GCT) of bone based on: - Age 32 (post-skeletal maturity) - Epiphyseal-metaphyseal location in proximal tibia - Well-defined lytic lesion with hemosiderin on MRI - Size 4 cm (moderate) ### GCT Management Decision Tree ```mermaid flowchart TD A[GCT Diagnosis Confirmed]:::outcome --> B{Surgical Candidate?}:::decision B -->|Yes| C{Lesion Characteristics}:::decision C -->|Small, Accessible| D[Intralesional Curettage + Bone Graft/Cement]:::action C -->|Large, Aggressive, Recurrent| E[Consider Wide Excision]:::action B -->|No/Aggressive| F[Denosumab Neoadjuvant]:::action D --> G[Adjuvant Denosumab for High-Risk Features]:::action E --> H[Reconstruction + Adjuvant Therapy]:::action F --> I[Re-assess for Surgery]:::decision I -->|Responsive| D I -->|Refractory| J[Continue Denosumab]:::action ``` ### Why Intralesional Curettage is Standard | Aspect | Intralesional Curettage | Wide Excision | Observation | |--------|------------------------|---------------|-------------| | **Indication** | Most GCTs (80%) | Recurrent, aggressive, pathologic fracture | Not recommended for symptomatic lesions | | **Functional Outcome** | Excellent joint preservation | Good but more morbidity | High recurrence risk | | **Recurrence Rate** | 10–25% (higher without adjuvant) | <5% | Progression likely | | **Adjuvant Options** | Denosumab, phenol, cryotherapy | Denosumab if high-risk | N/A | **High-Yield:** GCT is **benign but locally aggressive**. Intralesional curettage is the gold standard for primary lesions; wide excision is reserved for recurrent, pathologic fracture, or anatomically unfavorable cases. ### Adjuvant Strategies to Reduce Recurrence 1. **Mechanical adjuvants:** - Bone graft (allograft or autograft) - Polymethylmethacrylate (PMMA) cement - Cryotherapy (liquid nitrogen) 2. **Biological adjuvants:** - **Denosumab** (RANKL inhibitor) — increasingly used for high-risk cases (giant cell-rich, recurrent, or if wide excision not feasible) - Phenol (less commonly used now) **Clinical Pearl:** Denosumab is particularly valuable in: - Recurrent GCT - Lesions in anatomically critical locations (sacrum, distal femur near joint) - Patients unwilling or unfit for surgery - Neoadjuvant therapy to downstage aggressive lesions ### Why Other Options Are Wrong **Wide excision** is reserved for: - Recurrent GCT after failed curettage - Pathologic fracture - Sacral GCT (high recurrence with curettage alone) - Lesions with cortical breakthrough and soft-tissue extension This patient has a primary, well-demarcated, accessible lesion — wide excision would be overtreatment. **Observation** is never appropriate for symptomatic GCT. These lesions are locally aggressive and will progress, risking pathologic fracture and further joint damage. **Chemotherapy** has no role in GCT (it is benign, not malignant). [cite:Rockwood & Green's Fractures in Adults Ch 33; Orthopedic Surgery Principles & Practice 3e Ch 52]